# Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma

> **NCT02203864** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 49 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** BIBW2 component A
- **BIOLOGICAL:** BIBW2 component B

## Key facts

- **NCT ID:** NCT02203864
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-08
- **Primary completion:** 2001-02
- **Final completion:** —
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2014-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02203864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02203864, "Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02203864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*